Relapsed or Refractory Solid Tumors
Showing 1 - 25 of >10,000
Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)
Not yet recruiting
- Solid Tumor
- HLA-G-CAR.BiTE allogeneic γδ T cells
-
Taichung, Non-US, TaiwanChina Medical University Hospital
Nov 27, 2023
Solid Tumor Trial in Dallas (Atezolizumab, Vincristine, Irinotecan)
Not yet recruiting
- Solid Tumor
- Atezolizumab
- +3 more
-
Dallas, TexasThe University of Texas Southwestern Medical Center
Aug 30, 2022
Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor Trial in Valhalla (Vorinostat)
Recruiting
- Ewing Sarcoma
- +5 more
-
Valhalla, New YorkNew York Medical College
Oct 24, 2022
Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)
Recruiting
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2023
Relapsed or Refractory Lymphomas, Advanced Solid Tumor Trial in Los Alamitos (LP-284)
Not yet recruiting
- Relapsed or Refractory Lymphomas
- Advanced Solid Tumor
-
Los Alamitos, CaliforniaCancer and Blood Specialty Clinic
Nov 9, 2023
Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)
Withdrawn
- Relapsed Solid Neoplasm
- +2 more
- STI-3258
- (no location specified)
Jan 24, 2023
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma Trial in Washington (Cryoablation Therapy, Nivolumab, Ipilimumab)
Recruiting
- Osteosarcoma
- +9 more
- Cryoablation Therapy
- +2 more
-
Washington, District of ColumbiaChildren's National Hospital
Mar 21, 2022
Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)
Not yet recruiting
- Non-Hodgkin's Lymphoma, Relapsed
- +2 more
- (no location specified)
Dec 6, 2022
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)
Recruiting
- Clear Cell Renal Cell Carcinoma
- +4 more
- CTX131
-
Nashville, TennesseeResearch Site 1
Mar 21, 2023
Lymphoma, Solid Tumors Trial in Guangzhou (Mitoxantrone Hydrochloride Liposome)
Recruiting
- Lymphoma, Solid Tumors
- Mitoxantrone Hydrochloride Liposome
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 14, 2022
TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSX01-TCRT injection)
Recruiting
- TCR-T Cells
- +2 more
- KSX01-TCRT injection
-
Nanning, Guangxi Zhuang Autonomous Region, ChinaThe first affiliated hospital of Guang Xi medical university
Mar 31, 2023
Head Neck Cancer, Melanoma, Breast Cancer Trial in Shanghai (Recombinant L-IFN adenovirus injection)
Recruiting
- Head and Neck Cancer
- +6 more
- Recombinant L-IFN adenovirus injection
-
Shanghai, Shanghai, ChinaShanghai Fengxian District Central Hospital
Jan 16, 2022
Solid Tumor Metastatic Cancer Advanced Cancer Trial (TJ210001)
Available
- Solid Tumor Metastatic Cancer Advanced Cancer
- (no location specified)
Aug 19, 2022
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,
Recruiting
- Advanced Solid Tumors
- +2 more
- GIC-102 (Allogeneic NK cells)
-
Gyeonggi-do, Korea, Republic of
- +3 more
May 18, 2023
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)
Not yet recruiting
- Advanced Solid Tumor
- Refractory Non-Hodgkin Lymphoma
- (no location specified)
May 28, 2023
Advanced Solid Tumors, Relapsed Or Refractory Non-Hodgkin Lymphoma Trial in Zhengzhou, Hangzhou (YH004)
Not yet recruiting
- Advanced Solid Tumors
- Relapsed Or Refractory Non-Hodgkin Lymphoma
-
Zhengzhou, Henan, China
- +1 more
Oct 20, 2022
TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSH01 injection)
Recruiting
- TCR-T Cells
- +2 more
- KSH01 injection
-
Nanning, Guang XI, ChinaThe first affiliated hospital of Guang Xi medical university
Sep 14, 2022
Lung Cancer, Bronchial Cancer, Non Small Cell Lung Cancer Trial in Anqing (Recombinant oncolytic herpes simplex virus type 1
Recruiting
- Lung Cancer
- +11 more
- Recombinant oncolytic herpes simplex virus type 1 (R130)
-
Anqing, Anhui, ChinaThe PLA Navy Anqing Hospital
May 23, 2023
Refractory Solid Tumors, Relapsed Solid Tumors Trial in Beijing (KSX01-TCRT cell therapy)
Recruiting
- Refractory Solid Tumors
- Relapsed Solid Tumors
- KSX01-TCRT cell therapy
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Nov 21, 2023